Viewing data from:

IDOSE TR

NDA

TRAVOPROST | N218010 | GLAUKOS CORP

1 strength4 unique patents1 unique exclusivity

Patent Timeline

4 unique patents, 1 exclusivity by expiration date

Active (4)TodayExclusivity

2027

2028

2029

2030

2031

Today

Oct. 17, 2030

Oct. 17, 2030

Feb. 14, 2031

Jun. 18, 2030

Dec. 13, 2026

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain14 active DMFs3 inactive

13 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDTRAVOPROST

DMF 148902000

VERANOVA LPTRAVOPROST (3031.H)

DMF 220882008

CAYMAN PHARMA SROTRAVOPROST

DMF 222892008

CHIROGATE INTERNATIONAL INCTRAVOPROST

DMF 227382009

CURIA WISCONSIN INCTRAVOPROST ACTIVE DRUG SUBSTANCE

DMF 228352009

SCINOPHARM TAIWAN LTDTRAVOPROST USP

DMF 234232009

YS LIFE SCIENCE CO LTDTRAVOPROST

DMF 249072011

DELTA BIOTECH SATRAVOPROST

DMF 261802012

LUPIN LTDTRAVOPROST USP

DMF 268782013

MSN LABORATORIES PRIVATE LTDTRAVOPROST USP [ROUTE CODE - "TS"]

DMF 278632014

CHIROGATE INTERNATIONAL INCTRAVOPROST (ISOMER FREE)

DMF 329642018

GENTEC SATRAVOPROST

DMF 343702020

EUROAPI HUNGARY LTDTRAVOPROST

DMF 347422020

ZHEJIANG AUSUN PHARMACEUTICAL CO LTDTRAVOPROST

DMF 400182024

EVERLIGHT CHEMICAL INDUSTRIAL CORPInactiveTRAVOPROST

DMF 252632011

BIOCON LTDInactiveTRAVOPROST USP DRUG SUBSTANCE

DMF 257032012

EUROAPI HUNGARY LTDInactiveTRAVOPROST

DMF 294182015

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Jan 28, 2026	SUPPL -4	View Letter (PDF)
Jan 28, 2026	SUPPL -6	View Letter (PDF)
Dec 14, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 75MCG

RLD

4 patents1 exclusivity▴

IMPLANT;INTRACAMERAL | Approved: Dec 13, 2023

Patents (4)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
10206813	Oct 17, 2030	—	—	Yes	—	—
11426306	Oct 17, 2030	—	—	Yes	—	—
12201555	Feb 14, 2031	—	Yes	Yes	—	—
12201557	Jun 18, 2030	—	Yes	Yes		—

Exclusivities (1)

Code	Date	Status
NP	Dec 13, 2026	< 1 year